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INTRODUCTION
E-cadherin is a cell-cell adhesion molecule which is anchored
to the cytoskeleton via catenins and acts as a suppressor of
tumor invasion and metastasis (1, 2). Reduced expression of
E-cadherin has been associated with invasion and recurrence
of hepatocellular carcinomas (HCCs) (3). Somatic mutations
of E-cadherin are found in poorly differentiated breast and gas-
tric cancers (4, 5) but have not been described to date in HCC.
However, the allelic deletion of E-cadherin and neighboring
loci (6) and the hypermethylation of E-cadherin (7) have been
observed in HCCs.
DNA methylation is one of the best-understood epigenet-
ic changes in human cancers. DNA methylation may play
roles in carcinogenesis by virtue of 3 mechanisms: 1) DNA
cytosine methylation facilitates gene mutation, as 5-methyl-
cytosine is deaminated to thymine (8); 2) aberrant DNA
methylation may be associated with allelic loss (9); and 3)
DNA methylation occurs frequently in CpG islands near
regulatory regions of genes and affects the transcriptions of
specific genes (7). Promoter region CpG islands are protect-
ed from methylation in normal cells, excepting genes on the
inactive X chromosome and imprinted genes (10). This pro-
tection is critical, since the methylation of promoter region
CpG islands is associated with the loss of expression of these
genes (11). CpG methylation has recently been shown to be
an important mechanism in the transcriptional inactivation
of E-cadherin (12), and CpG methylation around the promot-
er region of E-cadherin was found to be significantly correlat-
ed with reduced E-cadherin expression in HCCs (7). Recent
studies reported that loss of heterozygosity (LOH) and pro-
moter methylation of E-cadherin occurred in different stages
of HCCs (6) and that promoter methylation of E-cadherin was
more frequent in HCCs retaining both alleles of the gene than
in LOH-bearing HCCs (13).
The two general explanations of the histogenesis of HCC
are de novo hepatocarcinogenesis, namely cancer development
directly from non-neoplastic hepatocytes, and multistep hepa-
tocarcinogenesis. Dysplastic nodules (DNs) have been describ-
ed as precancerous lesions in multistep hepatocarcinogenesis
(14), i.e., DN progresses to DN with microscopic foci of HCC
and then to HCC. Some cases of HCC may progress further
to become more malignant, with the possibility of metastases.
But, a few reports are available on the genetic and epigenetic
changes of E-cadherin in DNs (15). Despite recent advances
in diagnostic modalities and therapies, the long-term survival
of HCC patients remains poor because of its high incidence
of recurrence after initial treatment.
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Promoter Methylation of E-cadherin in Hepatocellular Carcinomas and
Dysplastic Nodules
In order to clarify the significance of E-cadherin methylation in multistep hepato-
carcinogenesis, we examined the methylation status of the E-cadherin promoter
region, using methylation-specific polymerase chain reaction in 64 hepatocellular
carcinomas (HCCs) and 13 dysplastic nodules (DNs), and correlated these results
with E-cadherin protein expression and clinicopathologic factors of HCCs. Promot-
er methylation was detected in 1 of 13 (7.7%) DNs, in 5 of 13 (38.5%) Edmondson
and Steiner grade I HCCs, and in 27 of 51 (52.9%) grade II or III HCCs, and a sig-
nificant correlation was observed between the methylation status and the stepwise
progression of hepatocarcinogenesis (p=0.004). Reduced E-cadherin immunore-
activity was found in 18 of 64 (28%) HCCs, but in none of DNs. E-cadherin methy-
lation status in HCCs was significantly correlated with microvascular invasion
(p=0.02) and tumor recurrence (p=0.04), but not with reduced E-cadherin immuno-
reactivity. The Kaplan-Meier method showed that methylation status did not have
a significant influence on the recurrence-free survival of HCC patients (p=0.15).
Our results indicate that methylation of the E-cadherin promoter region is a frequent
event in HCC, which may play an important role in the stepwise progression of
hepatocarcinogenesis. And the promoter methylation of E-cadherin in HCC was
found to be significantly correlated with microvascular invasion and recurrence.
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In this study, we investigated the methylation status of E-
cadherin and E-cadherin protein expression in HCCs and DNs
to clarify the significance of E-cadherin methylation in mul-
tistep hepatocarcinogenesis. We further analyzed the corre-
lations between the methylation status of E-cadherin and E-




Fresh samples of 64 HCCs and 13 DNs were obtained from
72 Korean patients at the Samsung Medical Center, Seoul,
Korea, between 1999 and 2003. Informed consent was obtain-
ed from each patient included in this study. Twelve specimens
were livers removed at orthotopic transplantation for HCC,
and 60 were from curative surgical resections for HCC. None
of the patients had received preoperative chemotherapy. Imme-
diately after hepatectomy for primary HCC, fresh liver tissues
were serially sliced at 4-5 mm intervals and then carefully
examined by a pathologist for the presence of DNs and HCCs,
which may be distinguished from the surrounding parenchy-
ma by color, texture, or degree of bulging on the cut surface.
Halves of the samples were snap-frozen in liquid nitrogen and
stored at -80℃. The remaining halves were fixed in 10%
neutral formalin to confirm the morphological diagnosis. DNs
were histologically diagnosed according to the guidelines
issued by the International Working Party (14), and HCCs
were graded histologically according to the Edmondson and
Steiner’s criteria (16). Nontumorous livers showed cirrhosis
in 58 patients and chronic hepatitis in 14. All patients were
seropositive for hepatitis B surface antigen and had no serum
antibody against hepatitis C virus. Patients ages ranged from
26 to 66 yr, with a median of 49.9 yr. The male-to-female
ratio was 57:15. DNs ranged from 10 to 22 mm in longest
diameter, with a median of 16.3 mm. There were 7 cases of
low grade DN and 6 cases of high grade DN. The longest
diameters of HCCs ranged from 11 to 140 mm, with a medi-
an of 45.8 mm. There were 13 cases of Edmondson & Steiner
grade I, 39 grade II, and 12 grade III HCC. The histopatho-
logic features of HCCs examined were tumor capsule forma-
tion, major portal vein invasion, microvascular invasion, tumor
stage, tumor size, and histological differentiation. Microvas-
cular invasion was considered as present when at least one or
more endothelial cells or the tunica media of a vessel were
observed to surround a neoplastic cell group. Tumor stage
was determined according to the AJCC cancer staging cri-
teria (17).
Immunohistochemistry
Formalin-fixed, paraffin-embedded tissues including both
HCC or DN and adjacent nontumorous tissue were sectioned
with 4  m thickness. Immunohistochemical studies were per-
formed using the streptavidin-biotin complex method and a
TechMateTM 1000 automated staining system (DakoChem-
mate, Glostrup, Denmark). Primary monoclonal antibody
against E-cadherin (clone 4A2C7) was purchased from Zymed
Lab Inc. (San Francisco, CA, U.S.A.) and used at 1:40 dilu-
tion. Deparaffinized sections were treated with 3% hydrogen
peroxide in methanol for 10 min to block endogenous per-
oxidase. Sections were processed in 0.05 M citrate buffer (pH
6.0) and heated in a microwave oven for 10 min for antigen
retrieval. Sections were then incubated with the primary anti-
body for 60 min at 37℃. 3,3 -diaminobenzidine tetrahydro-
chloride was used as a chromogen, and Mayer’s hematoxylin
counterstain was applied. Negative controls were run simul-
taneously with an omission of primary antibody. Blocks of
normal liver tissues were prepared as controls from the nor-
mal liver tissues of five patients with metastatic colonic car-
cinoma of the liver.
Strong intercellular and contiguous membranous staining
was considered positive for E-cadherin expression. Staining
results were evaluated by two independent pathologists and
any interpretational differences were resolved by consensus.
In accordance with previously published criteria (7), tumors
were considered maintained immunoreactivity for E-cadherin
when ≥50% of tumor cells showed strong membranous stain-
ing, and reduced immunoreactivity when >50% of tumor
cells lacked or showed only slight membranous staining.
Methylation-specific PCR (MSP)
DNA methylation patterns in the E-cadherin promoter
region were determined by MSP. Genomic DNA was obtained
from fresh HCC or DN. DNA (1  g) in a volume of 50  L
was denatured using NaOH (final concentration, 0.2 M) for
10 min at 37℃. Thirty  L of 10 mM hydroquinone and 520
L of 3 M sodium bisulfite (pH 5), both freshly prepared, were
then added and mixed, and samples were incubated under
mineral oil at 50℃ for 16 hr. Modified DNA was purified
using the Wizard DNA purification resin according to the
manufacturer’s instructions and then eluted into 50 L of
water. Modification was completed by treating with NaOH
(final concentration, 0.3 M) for 5 min at room temperature,
followed by ethanol precipitation. DNA was resuspended in
water and either used immediately or stored at -20℃.
Bisulfite-modified DNA was amplified using methylated-
specific primers (E-cad-M) 5′ -TTAGGTTAGAGGGTTAT-
CGCGT (sense) and 5′ -TAACTAAAAATTCACCTACCG-
AC (antisense) or unmethylated-specific primers (E-cad-U)
5′ -TAATTTTAGGTTAGAGGGTTATTGT (sense) and 5′ -
CACAACCAATCAACAACACA (antisense), which were
designed for the E-cadherin promoter region by Herman et al.
(18). These primers contained six sites (116 bp) of the CpG
promoter at genomic position of -205 for E-cad-M and five
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sites (97 bp) at genomic position of -201 for E-cad-U, respec-
tively (18). The PCR mixture contained 1×PCR buffer (16.6
mM ammonium sulfate/67 mM Tris, pH 8.8/6.7 mM MgCl2/
10 mM 2-mercaptoethanol), dNTPs (each at 1.25 mM), pri-
mers (300 ng of each per reaction), and bisulfite-modified
DNA (50 ng) in a final volume of 50  L. PCR conditions
were as follows: 95℃ for 5 min before adding 1.25 units of
Taq polymerase; then 33 cycles of 95℃for 30 sec, 57℃for
30 sec for methylated-specific primers or 53℃ for 30 sec for
unmethylated-specific primers, 72℃ for 30 sec; and finally
4 min at 72℃. Controls without DNA were performed for
each PCR set. The product of each PCR (10  L) was loaded
directly into nondenaturing 6-8% polyacrylamide gels, stained
with ethidium bromide, and visualized directly under UV
illumination.
Statistical analysis
The chi-square test was used, and significance was accept-
ed at p<0.05. Survival curves were plotted using the Kaplan-
Meier method to assess the correlations between the various
factors and survival. Differences between survival curves were




Diffuse strong membranous staining of E-cadherin was
detected in the hepatocytes in the 5 normal liver tissues. Most
areas of hepatocytes in nontumorous cirrhotic or chronic hep-
atitic liver tissues showed diffuse strong membranous stain-
ing of E-cadherin. Intrahepatic bile ducts showed strong and
homogeneous membranous staining and thus served as an
internal standard of positive staining.
Maintained immunoreactivity for E-cadherin was observed
in all 13 DNs (100%) and 46 of the 64 (72%) HCCs. Reduced
E-cadherin immunoreactivity was found in 18 of 64 (28%)
HCCs:1 of 13 (7.7%) Edmondson and Steiner grade I, 12 of
39 (30.8%) grade II, and 5 of 12 (41.7%) grade III HCCs
(Fig. 1). Reduced E-cadherin immunoreactivity was not cor-
related with tumor capsule formation, major portal vein inva-
sion, microvascular invasion, tumor recurrence, tumor stage,
tumor size, or histological differentiation of HCCs.
Promoter methylation of E-cadherin
Methylation of the E-cadherin promoter region was detect-
ed in 1 high grade DN and 32 of 64 (50%) HCCs (Fig. 2).
One of 13 (7.7%) DNs, 5 of 13 (38.5%) Edmondson and
Steiner grade I HCCs, and 27 of 51 (52.9%) grade II or III
HCCs were positive for methylation, showing a significant
correlation between the methylation status and the stepwise
progression of hepatocarcinogenesis (p=0.004). Reduced E-
cadherin immunoreactivity was found in 11 of 32 (34.3%)
HCCs with promoter methylation of E-cadherin and in 7 of
32 (21.9%) HCCs without promoter methylation. Methyla-
Fig. 1. Immunohistochemical analysis of E-cadherin in dysplastic nodule and hepatocellular carcinoma. (A) Maintained E-cadherin immunore-
activity in a dysplastic nodule and adjacent nontumorous liver. (B) Reduced immunoreactivity in hepatocellular carcinoma Edmondson
and Steiner grade III. (×100). N, nontumorous liver.
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Fig. 2. Representative examples of methylation-specific PCR anal-
ysis of E-cadherin in a dysplastic nodule (DN) and in hepatocel-
lular carcinomas (HCCs). DNA extracted from 77 liver tissues was
modified with sodium bisulfite and then amplified with primers
specific for the unmethylated (U) or methylated (M) CpG islands
of E-cadherin. G, Edmondson and Steiner Grade.
150 bp
100 bp
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tion status was found to be significantly correlated with micro-
vascular invasion (p=0.02) and tumor recurrence in HCCs
(p=0.04), but methylation status was not correlated with
reduced E-cadherin immunoreactivity, tumor capsule forma-
tion, or major portal vein invasion in HCCs. Methylation fre-
quencies were not found to be correlated with the tumor stage,
tumor size, or histological differentiation of HCCs (Table 1).
Survival analysis
After curative resection for HCC, 54 patients were followed
up at our outpatient clinic and received regular clinical assess-
ments to detect tumor recurrence. A diagnosis of recurrence
was based on an elevated serum  -fetoprotein level and radio-
logical evidence and/or biopsy. During the follow-up period
(median, 43 months; range, 22-53 months), 34 patients ex-
perienced tumor recurrence and 24 patients died of the dis-
ease. Tumors recurred in residual livers in all 34 cases.
Median survival time for the 54 patients was 51 months
and their median recurrence-free survival time was 18 months.
Median recurrence-free survival time was 22 months in methy-
lation-negative cases (n=29) and 14 months in methylation-
positive cases (n=26). The Kaplan-Meier method showed
that methylation status did not have a significant influence
on the overall survival (p=0.91) or the recurrence-free survival
of the 54 HCC patients (p=0.15; Fig. 3).
DISCUSSION
Work over the past several years has demonstrated that the
silencing of tumor suppressor genes associated with promot-
er methylation is a common feature in human cancers, and
that this serves as an alternative mechanism of loss of tumor
suppressor gene function (11). A growing number of genes
have been found to undergo promoter methylation in HCC,
which indicates the potential role of promoter methylation
in hepatocarcinogenesis. The down-regulation of E-cadherin
is related to allelic deletion of the gene or DNA hypermethy-
lation in the promoter region; both mechanisms have been
demonstrated in HCC (13, 19). Reduced expression of E-cad-
herin decreases intercellular adhesiveness, and may result in
the initiation of invasion and in the destruction of normal
tissue morphology (7). The reported frequency of E-cadherin
promoter methylation by MSP ranges from 33% to 49% in
HCCs (15, 20), though it is significantly lower in one study
(8.9%) (13). In the present study, we found a 50% frequency
of E-cadherin promoter methylation in HCC, which demon-
strates that it is a relatively frequent event. Kanai et al. (9)
reported no significant differences in the incidences of aber-
rant DNA methylation on chromosome 16 between HCCs
with hepatitis B or hepatitis C virus infection and HCCs with-
out either. 
DNs are precancerous lesions with a high risk of progres-
sion into HCCs. Lee et al. (15) detected the methylation of
the E-cadherin CpG island in 33.3% of HCCs, but did not
detect this methylation in all 22 DNs studied. In the present
study, E-cadherin was found to be methylated in DNs at a
frequency of 7.7% and methylation frequencies increased
significantly to 38.5% in grade I HCCs and 52.9% in grade
II or III HCCs. These results indicate that the increased fre-
quency of E-cadherin promoter methylation appears to be asso-
ciated with a more advanced stages of hepatocarcinogenesis,
and suggest that E-cadherin methylation might participate
in the stepwise progression of hepatocarcinogenesis. Some
steps of carcinogenesis involving non-mutational genetic alter-
Ed, Edmondson and Steiner grade; NS, not significant.
Parameters Methylation (+) Methylation (-) p value
Reduced E-cadherin 11/32 (34.3%) 7/32 (21.9%) NS
immunoreactivity
Tumor capsule 19/32 (59.4%) 23/32 (71.9%) NS
Major portal vein invasion 3/32 (9.4%) 4/32 (12.5%) NS
Microvascular invasion 22/32 (68.8%) 13/32 (40.6%) 0.02
Tumor recurrence 20/26 (76.9%) 14/28 (50%) 0.04
Tumor stage 1 10/29 (34.5%) 19/29 (65.5%) NS
2 18/27 (66.7%) 9/27 (33.3%)
3 3/7 (42.9%) 4/7 (57.1%)
4 1/1 (100%) 0/1 (0%)
Tumor size ≤2 cm 7/14 (50%) 7/14 (50%) NS
2-5 cm 14/26 (53.8%) 12/26 (46.2%)
>5 cm 11/24 (45.8%) 13/24 (54.2%)
Histological Ed I 5/13 (38.5%) 8/13 (61.5%) NS
differentiation Ed II 20/39 (51.3%) 19/39 (48.7%)
Ed III 7/12 (58.3%) 5/12 (41.7%)
Table 1. Correlations between E-cadherin promoter methyla-
tion and reduced E-cadherin immunoreactivity and the clinico-
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Fig. 3. Kaplan-Meier curves for recurrence-free survival in 54 patients
with HCC according to the methylation status of E-cadherin. Solid
line, patients without methylation. Dotted line, patients with methy-
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ations may be reversible, thus aberrant DNA methylation
might become a target for cancer prevention and therapy.
Recurrence after the successful surgical or nonsurgical treat-
ment of HCC is caused either by intrahepatic metastasis or
by metachronously multicentric occurrences. Intrahepatic
metastasis is a major cause of recurrence of advanced HCCs
with varying degrees of vascular invasion, and multicentric
occurrence is a frequent cause of recurrence in small HCCs
with no obvious vascular invasion. The inactivation of E-cad-
herin is involved in tumor invasiveness and metastatic poten-
tial (1). Moreover, promoter CpG island methylation is an
important mechanism of gene inactivation in human cancer.
In this study, we observed that promoter methylation of E-
cadherin was significantly correlated with microvascular inva-
sion and tumor recurrence. Promoter methylation of E-cad-
herin may participate in certain steps of hepatocarcinogene-
sis by reducing intercellular adhesiveness, which may result
in invasion and metastasis. In this study, reduced E-cadherin
immunoreactivity was not correlated with HCC recurrence.
These data are in agreement with a previous report (13), and
might reflect a high percentage of de novo onset of primary
tumors over truly relapsed HCCs. No significant correlation
was observed between reduced E-cadherin immunoreactivity
and microvascular invasion in HCC. This is at variance with
a previous report (13). The relation between reduced E-cad-
herin immunoreactivity and histopathologic features of HCCs
needs further study.
Lee et al. (15) reported that HCC patients with E-cadherin
methylation showed poorer overall survival than those with-
out. However, in the present study, no significant correlation
was observed between the methylation status of HCC and
survival. A recent study found that the methylation status of
E-cadherin promoter changed dynamically according to the
cellular microenvironment in the tumor (21). MSP is a remark-
ably sensitive method that can detect 0.1% of methylated
cells in a specimen (18), and methylation status on an all-or-
nothing basis may not directly predict the prognosis. Thus
the extent of methylated areas within a single tumor may
be more relevant to survival of HCC patients. 
Kanai et al. (7) reported a significant correlation between
CpG methylation around the promoter region and reduced
E-cadherin expression in HCCs. However, in the present study,
no significant correlation was found between the methylation
status of HCC and E-cadherin immunoreactivity, which is
consistent with previous reports (6, 13). Promoter methyla-
tion of E-cadherin was heterogeneous among cells in single
HCCs (19). Moreover, intratumoral E-cadherin expression
heterogeneity was noted in human cancers (22). Graff et al
(21) reported that breast cancers with minimal evidence of
E-cadherin methylation displayed generally strong E-cadherin
immunoreactivity, whereas those with prominent methylation
showed distinct, heterogeneous loss of E-cadherin immunore-
activity. Methylation status on an all-or-nothing basis may
not directly predict the E-cadherin immunoreactivity, and
the extent of methylated areas within a single tumor may be
more relevant to the E-cadherin immunoreactivity. In addi-
tion, we noted reduced E-cadherin immunoreactivity without
methylation in 21.9% of HCCs. This suggests that mecha-
nisms other than methylation are likely to be involved in im-
paired E-cadherin immunoreactivity. Dysfunction of catenins
or the effects of signals from other cell junctions might induce
the instability of translated E-cadherin molecules.
In conclusion, the methylation of the E-cadherin promoter
region was found to be a frequent event in HCC, and may
play an important role in the stepwise progression of hepa-
tocarcinogenesis. Moreover, the promoter methylation of E-
cadherin in HCC was found to be significantly correlated with
microvascular invasion and recurrence.
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